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Brain cholesterol synthesis and metabolism is progressively disturbed in the R6/
1 mouse model of Huntington's disease: a targeted GC-MS/MS sterol analysis
Abstract
Background:Cholesterol has essential functions in neurological processes that require tight regulation of
synthesis and metabolism. Perturbed cholesterol homeostasis has been demonstrated in Huntington's
disease, however the exact role of these changes in disease pathogenesis is not fully understood.
Objective:This study aimed to comprehensively examine changes in cholesterol biosynthetic precursors,
metabolites and oxidation products in the striatum and cortex of the R6/1 transgenic mouse model of
Huntington's disease. We also aimed to characterise the progression of the physical phenotype in these
mice. Methods:GC-MS/MS was used to quantify a broad range of sterols in the striatum and cortex of R6/
1 and wild type mice at 6, 12, 20, 24 and 28 weeks of age. Motor dysfunction was assessed over 28
weeks using the RotaRod and the hind-paw clasping tests. Results:24(S)-Hydroxycholesterol and
27-hydroxycholesterol were the major cholesterol metabolites that significantly changed in R6/1 mice.
These changes were specifically localised to the striatum and were detected at the end stages of the
disease. Cholesterol synthetic precursors (lathosterol and lanosterol) were significantly reduced in the
cortex and striatum by 6 weeks of age, prior to the onset of motor dysfunction, as well as the cognitive
and affective abnormalities previously reported. Elevated levels of desmosterol, a substrate of delta(24)sterol reductase (DHCR24), were also detected in R6/1 mice at the end time-point. Female R6/1 mice
exhibited a milder weight loss and hind paw clasping phenotype compared to male R6/1 mice, however,
no difference in the brain sterol profile was detected between sexes. Conclusion:Several steps in
cholesterol biosynthetic and metabolic pathways are differentially altered in the R6/1 mouse brain as the
disease progresses and this is most severe in the striatum. This provides further insights into early
molecular mediators of HD onset and disease progression and identifies candidate molecular targets for
novel therapeutic approaches.
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Abstract
Background: Cholesterol has essential functions in neurological processes that require tight
regulation of synthesis and metabolism. Perturbed cholesterol homeostasis has been
demonstrated in Huntington’s disease, however the exact role of these changes in disease
pathogenesis is not fully understood.
Objective: This study aimed to comprehensively examine changes in cholesterol biosynthetic
precursors, metabolites and oxidation products in the striatum and cortex of the R6/1
transgenic mouse model of Huntington’s disease. We also aimed to characterise the
progression of the physical phenotype in these mice.
Methods: GC-MS/MS was used to quantify a broad range of sterols in the striatum and cortex
of R6/1 and wild type mice at 6, 12, 20, 24 and 28 weeks of age. Motor dysfunction was
assessed over 28 weeks using the RotaRod and the hind-paw clasping tests.
Results: 24-Hydroxycholesterol and 27-hydroxycholesterol were the major cholesterol
metabolites that significantly changed in R6/1 mice. These changes were specifically
localised to the striatum and were detected at the end stages of the disease. Cholesterol
synthetic precursors (lathosterol and lanosterol) were significantly reduced in the cortex and
striatum by 6 weeks of age, prior to the onset of motor dysfunction, as well as the cognitive
and affective abnormalities previously reported. Elevated levels of desmosterol, a substrate of
delta(24)-sterol reductase (DHCR24), were also detected in R6/1 mice at the end time point.
Female R6/1 mice exhibited a milder weight loss and hind paw clasping phenotype compared
to male R6/1 mice, however, no difference in the brain sterol profile was detected between
sexes.
Conclusion: Several steps in cholesterol biosynthetic and metabolic pathways are
differentially altered in the R6/1 mouse brain as the disease progresses and this is most severe
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in the striatum. This provides further insights into early molecular mediators of HD onset and
disease progression and identifies candidate molecular targets for novel therapeutic
approaches.

Introduction
Huntington’s disease (HD) is a progressive neurodegenerative disease caused by the
expansion of a trinucleotide [cytosine-adenine-guanidine (CAG)] repeat on the N-terminus of
the huntingtin protein (HTT). The classical neuropathological hallmark of HD is the severe
atrophy of the striatum (caudate and putamen) [1], with substantial volume loss in the order
of 50%. This primarily manifests as involuntary movements (chorea) and cognitive
dysfunction. MRI techniques have also highlighted that the hippocampus, cerebral cortex,
globus pallidus and amygdala also have reduced volume in HD patients [2]. Among other
effects, the expansion of the CAG repeat on HTT has been reported to alter HTTphospholipid interactions [3], membrane organisation [4] and gene transcription of lipid
metabolic enzymes [5]. Several studies have also identified that cholesterol synthesis and
metabolism in HD cell lines and animal models is significantly disturbed [6-8] highlighting
possible mechanisms. However, further investigation into different sterol-related mechanisms
and metabolic pathways is necessary to examine their influence on HD pathophysiology.
Cholesterol is highly concentrated in the brain, the majority found in myelin, accounting for
70% of total cholesterol, with the remainder found in cellular membranes of neurons and glial
cells. Maintenance of cholesterol levels is essential for many neurological functions including
dendritic maintenance [9], synaptogenesis [10] and axon growth [11]. Genetic defects that
alter cholesterol synthetic enzymes can have severe consequences [12,13], especially in the
brain where tight regulation of cholesterol synthesis is essential for normal neuronal function.
3
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The blood brain barrier (BBB) is impermeable to cholesterol, preventing fluctuations in
circulating cholesterol affecting brain levels. Brain cholesterol is derived from de novo
synthesis, a pathway that involves over 20 steps. Cholesterol biosynthetic regulation is
thought to involve a complex interplay between sterol sensing elements [sterol regulatory
element-binding proteins (SREBPs)] and transcription factors responsible for producing
cholesterol synthetic enzymes [14]. However, recent evidence suggests that further regulation
of cholesterol synthesis may occur in the later stages of the pathway [15,16]. The later stages
of the cholesterol biosynthetic pathway are branched into the Kandutsch-Russell and Bloch
pathways. Several cholesterol synthetic precursors exist in these pathways that occur
downstream of squalene (see Fig. 1). Although the rate of cholesterol synthesis in peripheral
tissues can be estimated by plasma levels of cholesterol synthetic precursors (lathosterol and
lanosterol), these do not reflect central nervous system (CNS) cholesterol synthesis. Direct
measurement of sterol precursor levels in brain tissue is therefore necessary to monitor the
cholesterol synthetic pathway [7,8,17].
24-Hydroxycholesterol (24-OHC) has been marked as a molecule of interest after being
identified as a major and specific elimination product of cholesterol from the brain [18,19].
Side chain hydroxylation of cholesterol increases membrane permeability and enables
movement across the BBB into circulation. 24-OHC is formed enzymatically from CNS
cholesterol catalysed by cholesterol 24-hydroxylase (CYP46A1), which is primarily
expressed in neurons [20]. Plasma 24-OHC levels have been suggested as a marker of
metabolically active neurons in the brain [19], and have been shown to be reduced in the
plasma of HD patients [21,22] and in brain tissue of several rodent models of HD [8].
Furthermore, an association between altered CYP46A1 activity and 24-OHC levels has been
reported in other neurodegenerative diseases [23-26], however the role of these changes in
HD pathogenesis are unknown.
4
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27-Hydroxycholesterol (27-OHC) is a major metabolic product of cholesterol in peripheral
tissue, entering the bloodstream to be further metabolised in the liver [27,28]. The enzyme
cholesterol 27-hydroxylase (CYP27A1) catalyses the formation of 27-OHC. A concentration
gradient results in a net movement of 27-OHC from circulation into the brain [29], where it is
quickly metabolised into more polar products (including dihydroxysterols and cholestenoic
acids), catalysed by CYP27A1 and 5-hydroxycholesterol 7-α-hydroxylase (CYP7B1) [30].
Although 27-OHC has been reported to be elevated in Alzheimer’s disease (AD) brain tissue
[31,32], the importance of this metabolic pathway has not been established in other
neurodegenerative diseases, including HD.
Oxidative damage to biological macro molecules is a major component of neurodegenerative
diseases, including AD [33] and Parkinson’s disease (PD) [34]. Free radical mediated
oxidation of cholesterol in the 5,6 position forms 7β-hydroxycholesterol (7β-OHC) and 7ketocholesterol (7-KC). An elevation of these cholesterol oxidation products (COPs) has been
reported in several diseases and pathological models that involve oxidative stress [35-38].
Due to the high concentration of cholesterol in the brain, COPs represent potentially
important biomarkers for oxidative stress in neurodegenerative diseases.
Perturbed cholesterol synthetic and metabolic pathways have been previously reported in HD
mouse and cell models [5-7,17]. Due to the complexity of the cholesterol synthetic pathway,
previous studies have measured some of the major brain synthetic sterol intermediates and
metabolites, but the full extent of potential sterol alterations that may occur in different brain
regions has not been fully examined. In this study we have used an accurate and sensitive
GC-MS/MS technique to characterise cholesterol pathway alterations occurring in the
striatum and cortex of the R6/1 mouse model. Physical phenotypic changes were also
examined including, impaired motor performance, weight loss, reduced brain mass and
involuntary clasping. Analysis of multiple time points and two different brain regions aimed
5
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to establish when specific alterations of cholesterol synthetic and metabolic pathways may
occur during the progression of HD in the R6/1 mouse model.

Materials and Methods
Materials
Desmosterol-d6, zymosterol-d5, zymosterol and lanosterol-d6 were obtained from Avanti
lipids (Alabaster, AL, USA). Tert-butylhydroxytoluene (BHT), cholesterol, -cholestane, 7hydroxycholesterol, 7-dehydrocholesterol and 7-ketocholesterol were from Sigma (St. Louis,
MO, USA). Lathosterol, lanosterol, desmosterol and 27-hydroxycholesterol were obtained
from Steraloids (Newport, RI, USA). 7-hydroxycholesterol-d7, lathosterol-d4 and 7ketocholesterol-d7

were

purchased

from

CDN

Isotopes

(Quebec,

Canada).

27-

hydroxycholesterol-d5, 24-hydroxycholesterol and 24-hydroxycholestero-d7 were from
Medical Isotopes, Inc (Pelham, AL, USA). 24,25-dihydrolanosterol-d6 was obtained from
Toronto research chemicals (TRC, Ontario, Canada). All standards obtained were of the
highest purity (>95%). Methanol, hexane, methyl tert-butyl ether (MTBE), acetonitrile,
toluene, formic acid and NaOH were purchased from Ajax Finechem (Thermo Fisher
Scientific, AU). CUQAX223 UCT Clean-Up QAX2 solid phase extraction columns and
BSTFA (N,O-bis(trimethylsilyl) trifluoroacetamide) + 1% TMCS (trimethylchlorosilane)
was purchased from PM Separations (Qld, Australia).
Mice
Transgenic R6/1 male mice were provided by the Hannan Laboratory, Florey Institute of
Neurosciences and Mental Health, and bred with CBB6 (CBA x C57/B6) F1 female mice at
Australian Bio-Resources (Mossvale, Australia). Equal numbers of male and female R6/1 and
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wild type mice were housed in standard small rodent cages. At least two of each genotype
was housed per cage. Mice were provided with standard rodent diet ("rat & mouse nut", Vella
Stock Feeds, NSW, Australia) and water available ad libitum. Body weight was recorded
every 4-5 days from 7 weeks until sacrifice. All procedures that were undertaken conformed
to the standards of the University of Wollongong ethics committee (animal ethics approval
number: AE 13/20).
Behavioural testing
A RotaRod apparatus (TSE systems, Bad Homberg, Germany) was used to measure motor
performance of mice. Mice were acclimatised to the RotaRod over two days before initial
testing. The testing protocol involved a rotation of 4 RPM for 5 sec followed by a linear
acceleration from 4 to 40 RPM over 200 sec. The latency to fall was measured automatically
by the RotaRod using light beam sensors. This procedure was repeated (5 times in total) and
the average of the two longest run times was recorded for analysis. The hind paw clasping
phenotype was tested by suspending the mouse by the tail. Mice that clasped both hind paws
tightly to their body were considered to have a complete clasp phenotype. Mice that clasped
one paw or both paws in an interrupted manner were considered to have a "half clasp"
phenotype.
Brain tissue collection
Mice were euthanised using slow flow CO2 asphyxiation and perfused with 1 x PBS (4oC).
The head was then excised and the whole brain removed and weighted. Cerebral cortex and
striatum was dissected and snap frozen in liquid N2 and stored at -80oC prior to analysis.
Lipid extraction
Frozen brain tissue (~5-10 mg) was weighed directly into a 0.5 mL polypropylene tube
containing 5 Zircosil® ceramic beads (1.3 mm) (Klausen Pty Ltd, NSW, Australia), 150 µL
7
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methanol (0.01% BHT) and internal standards (4oC). Tissue was homogenised at 4°C using a
Precellys 24 homogeniser (Bertin Technologies) (2 x 20 s at 5,000 rpm) and the homogenate
was transferred to a clean glass vial. The tube and ceramic beads were washed with 100 µL
methanol (4°C) and was added to the homogenate with 250 µL of NaOH (1 M). The sample
was hydrolysed at room temperature for 16 h in the absence of light and then acidified with
330 µL of 1 M formic acid. The sample was made up to a final volume of 3 mL (8%
methanol, pH 4.5) by the addition of 2.2 mL milliQ water. Solid-phase extraction (SPE) was
carried out on a 200 mg mixed C8/anion exchange quaternary amine column (CUQAX223,
UCT Inc.) that had been preconditioned with 2 mL methanol and then 2 mL 40 mM formic
acid buffer (pH 4.5). The lipid extract was loaded and the column washed with 2 mL
methanol in 40 mM formic acid (40:60). The SPE column was dried with N2 gas flow for 5
min. Sterols and oxysterols were eluted in a single fraction with 2 mL hexane followed by 2
mL hexane/MTBE (50:50).
GC-MS/MS sterol analysis
The sterol/oxysterol fraction was dried under N2 gas flow at 37°C and derivatised by the
addition of 20 µL acetonitrile and 20 µL BSTFA + 1% TMCS for one hour at 37oC. Samples
were dried under N2 and immediately reconstituted in 40 µL toluene for GC-MS/MS
analysis. Selective reaction monitoring (SRM) analysis of sterols/oxysterols was carried out
on an Agilent 7000B triple quadrupole mass selective detector interfaced with an Agilent
7890A GC system gas chromatograph. Quantification was performed by Agilent Masshunter
Quantitative software (V B.05.00) by comparison of specific SRM transitions with their
corresponding heavy isotopes and using relative response factor calibration. Cholesterol was
quantified using the internal standard α-cholestane in a separate injection and
chromatographic run.
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Statistical analysis
Linear regression analysis was used to identify the rate of weight gain between genotypes and
identify the relationship between age and sterol changes in mice. A 2-way ANOVA was used
to analyse RotaRod performance, body weight, brain lipid and brain mass data, with
Bonferroni post-tests to compare means at individual time points. A student’s t test was also
used to compare sterols levels between sexes and at individual time points in the sterol data.
P-values < 0.05 were considered significant. All analyses were performed in Graphpad
PRISM v5.0 (Graphpad Software Inc., USA).

Results
Physical phenotype
The cohort of R6/1 and WT littermates housed until 28 weeks of age (n = 5 per genotype and
sex) were tested periodically for physical changes that characterise the progression of the HD
phenotype. These results are represented in Fig. 2.
Weight loss in R6/1 mouse
Male and female R6/1 body weight was significantly reduced compared to WT mice over the
course of the study (p < 0.0001, Fig. 2A). The mean body weight of R6/1 mice did not
increase after 16 weeks of age in males, and 19 weeks in females. Prior to weight loss (7-19
weeks) the rate of weight gain was significantly less in female R6/1 mice compared to WT (p
= 0.00012). No significant difference in the rate of weight gain was detected between male
R6/1 and WT mice in the 6-16 week period. By 28 weeks the average weight increase from
the earliest measurement (7 weeks) was 8% in R6/1 males and 19% in R6/1 females.
Hind-paw clasping phenotype
9
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The hind-paw clasping phenotype was previously observed in R6/1 and R6/2 mice [39]. In
our study the clasping phenotype was first observed at 12 weeks in males (Fig. 2B), with the
percentage of mice showing positive for the phenotype increasing to 60% at the end of the
study. Female R6/1 mice first exhibited the clasping phenotype at the age of 17 weeks (Fig.
2B). The percentage of female R6/1 mice showing the phenotype increased to 60% by the
end of the study. A small proportion of WT mice showed a positive "half clasp" phenotype at
varying times throughout the study.
Motor performance
The average latency to fall from the RotaRod was significantly less in R6/1 mice compared to
WT in both males (p = 0.0016) and females (p = 0.0004) over the course of the study (Fig.
2C). No difference in the RotaRod performance was detected between genders of the same
genotype.
Brain mass
The brain mass of both male and female R6/1 mice was significantly less than WT littermates
at later time points (Fig. 3). The difference between WT and R6/1 male mice was highly
significant at 20, 24 and 28 weeks (p < 0.0001). In female mice a significant difference was
detected at 12 and 20 weeks (p < 0.05), becoming highly significant at 24 and 28 weeks (p <
0.0001).

Sterol analysis of R6/1 brain tissue
Tissues from both male and female R6/1 and WT mice were investigated in the sterol
analysis. Minor differences in the sterol profile between male and female mice of the same
genotype were identified (Supplemental Table 1-2), however these did not influence the
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differences identified between WT and R6/1 mice. Therefore to increase statistical power,
both sexes were combined and reanalysed. The level of all sterols measured for the individual
sexes can be found in Supplemental Table 1-2. The following results summarise the data for
combined sexes.

Cholesterol synthetic precursors
Several cholesterol synthetic precursors were significantly decreased in R6/1 striatum and
cortex compared to WT (Figs. 3.5A-D, 3.6A-D). Lathosterol levels were significantly
reduced from the pre-symptomatic age of 6 weeks in R6/1 striatum (p < 0.001) and cortex (p
< 0.05) when compared to WT mice. Lathosterol was consistently reduced in both cortex and
striatum of R6/1 mice compared to WT at all later time points (12, 20, 24 and 28 weeks; p <
0.001, Figs. 4A, 5A). Lanosterol and zymosterol followed a similar consistent reduction; a
significant difference in lanosterol levels was first detected at 12 weeks in striatum (Fig. 4B)
and cortex (Fig. 5B) of R6/1 (striatum p < 0.01, cortex p < 0.05). R6/1 striatum exhibited an
early reduction in zymosterol at 6 weeks (p < 0.01), and at all later time points (Fig. 4C). The
level of zymosterol in cortex tissue was only significantly reduced compared to WT at 28
weeks of age (p < 0.05, Fig. 5C). The cholesterol synthetic precursor 24,25 dihydro lanosterol
was not significantly altered in the R6/1 striatum or cortex although it was detected at lower
mean levels than WT at all time-points examined (Figs. 4D, 5D).
Lathosterol, lanosterol, zymosterol and 24,25 dihydro lanosterol levels decreased over time in
the striatum of both WT and R6/1 mice (Fig. 4A-D, p < 0.01). In the cortex, lanosterol,
zymosterol and 24, 25 dihydro lanosterol decreased significantly over time in R6/1 mice but
not WT (Fig. 5B, C, D, p < 0.05). Lathosterol decreased significantly over time in the cortex
of both R6/1 and WT mice (Fig. 5A, p < 0.05).
11
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Unlike upstream sterols in the cholesterol synthetic pathway, desmosterol levels did not
significantly decrease over time in the striatum of R6/1 mice (Fig. 4E). Comparing the means
between R6/1 and WT mice at individual time points identified desmosterol was significantly
elevated in R6/1 striatum at 20 and 28 weeks compared to WT (t-test, p = 0.046 and p =
0.0138 respectively, Fig. 4E). Desmosterol levels in cortex were also unaltered over time in
both WT and R6/1 mice. A small but significant elevation of desmosterol was detected in
R6/1 mice at 28 weeks (t-test, p = 0.0431, Fig. 5E). 7-dehydrocholesterol levels did not
decrease over time in cortex or striatum of R6/1 mice, and no difference between R6/1 and
WT mice was detected at any time point (Figs. 4F, 5F).
Cholesterol
Total cholesterol levels were not significantly altered between R6/1 and WT mice in this
study. However, an increase in cholesterol levels over time (6-28 weeks of age) was observed
both in striatum and cortex of WT and R6/1 mice (p < 0.05, Fig. 6).
Cholesterol metabolites
The brain specific cholesterol elimination product 24-OHC was significantly reduced in the
striatum of R6/1 mice at the end time point of 28 weeks (p < 0.01, Fig. 6). No other time
point or brain region measured showed an effect of genotype on 24-OHC levels. 24-OHC
levels increased in both striatum and cortex of WT and R6/1 mice over time (p < 0.01, Fig.
6).
27-OHC, a predominantly peripheral metabolite of cholesterol was consistently reduced in
R6/1 striatum from the age of 12 weeks (p < 0.05) and at all later time points (20 weeks p <
0.01, 24 weeks p < 0.05, 28 weeks p < 0.05, Fig. 6). 27-OHC levels were not significantly
altered in cortex tissue of R6/1 mice when compared to WT at any of the 5 time-points
examined (Fig. 6).
12
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Cholesterol oxidation products
Free radical generated oxidation products of cholesterol were also measured over the course
of the study. No significant differences in the level of 7-KC and 7β-OHC were detected
between R6/1 and WT in any brain region or timepoint measured (Supplemental Table 1-3).

Discussion
This is the first study to comprehensively examine progressive sterol changes in the R6/1
mouse model, and has investigated a greater number of cholesterol synthetic precursors and
metabolites than other studies of HD animal models to date. Previous studies examining
cholesterol changes in HD mouse models have focused on several major sterols in whole
brain homogenates at multiple time-points during disease progression, or in specific brain
regions at a single time-point. Recent studies suggesting more complex cholesterol synthetic
regulation in the later stages of the cholesterol synthetic pathway [15,16] highlights the
relevance of this study investigating a wider variety of cholesterol synthetic precursors.
Minor sterol differences between sexes did not influence differences detected between R6/1
and WT mice. Therefore, for simplicity the following discussion describes changes occurring
when sexes were combined. The significant reduction of lathosterol and zymosterol in the
striatum of R6/1 mice at 6 weeks of age represents the earliest detectable change in the R6/1
sterol profile, and appears before the onset of overt motor dysfunction as measured on the
RotaRod. In fact, 6 weeks of age in R6/1 mice also precedes the onset of cognitive deficits
[40,41] and affective abnormalities [42,43] in this HD model and therefore this sterol
dysregulation could contribute to cognitive, psychiatric and motor symptoms. Changes to
zymosterol are more specific to the striatum compared to other precursors that decrease early
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in both cortex and striatum. This highlights zymosterol as a possible specific biomarker of
early striatal changes in HD mice.
Synthetic precursor levels were more severely affected in striatum compared to cortex in our
study; changes occurred earlier and were of a greater magnitude in striatum (lathosterol
decreased by 80% in striatum compared with 50% in cortex). This observation is consistent
with previous studies in the yeast artificial chromosome (YAC 128) and R6/2 transgenic HD
mouse models [7,17]. The striatum is also the earliest and most severely affected region in
HD [1]. Absolute cholesterol and cholesterol synthetic precursor levels have been shown to
be higher in striatum compared to cortex [7,44], and for this reason it has been hypothesised
that disturbed cholesterol homeostasis in HD may lead to specific vulnerability of the
striatum [7]. Significant sterol changes early in the striatum of the R6/1 mouse suggest that
alterations to the cholesterol biosynthetic pathway in the brain occur very early; with the
possibility that these changes may even be present during embryonic development. Since the
majority of brain cholesterol is synthesised during prenatal life [45], HD neurodegeneration
may be seeded early, with individuals only becoming symptomatic later in life. A current
hypothesis suggests that errors in myelination during development may be a factor in human
HD, taking many years to manifest before onset due to compensatory mechanisms that
function early but become overwhelmed in the aged brain [46]. Alternatively, early changes
to cholesterol biosynthesis may be independent of the pathological processes in this HD
model.
This study has also examined 7-dehydrocholesterol and desmosterol; the immediate
precursors to cholesterol in the Kandutsch-Russell and Bloch pathways respectively (Fig. 1).
Contrary to a previous finding that desmosterol decreases in symptomatic YAC 128 mice (10
months of age) [17], desmosterol levels were significantly elevated in R6/1 striatum and
cortex by the end stage in our study. This may be a result of the different mouse models
14
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expressing different forms of mutant HTT (truncated or full length). In addition, analytical
discrimination of very similar sterols such as 7-dehydrocholesterol and desmosterol can be
challenging. The use of GC-MS/MS in our study provides greater specificity than single
quadrupole GC-MS that was used in the previous study [17]. Desmosterol elevation in R6/1
mice is unlikely a result of increased synthesis as cholesterol levels did not increase in our
study or in a previous study examining R6/1 mice [4]. A plausible explanation for this
accumulation is a reduced activity of the enzyme (DHCR24) that catalyses the conversion of
desmosterol to cholesterol. Previous studies in R6/2 mice do not report desmosterol levels
and therefore it is unknown if desmosterol accumulation also occurs in this related HD mouse
model that expresses a longer CAG repeat in the R6 transgene [7]. 7-Dehydrocholesterol
levels have not been previously reported in HD mouse brain, and in contrast to upstream
Kandutsch-Russell branch precursors the levels were not significantly altered over time and
between WT and R6/1 mice. Since lathosterol (the immediate precursor of 7dehydrocholesterol) levels are substantially reduced the enzyme that converts 7dehydrocholesterol to cholesterol (DHCR7) may also be less active or at lower abundance in
R6/1 mice.
The absolute level of cholesterol synthetic precursors (lathosterol and lanosterol) in brain
tissue has been proposed as a marker of the cholesterol synthetic rate [7,47]. However our
results suggest there is likely to be more complex regulation at various points of the synthetic
pathway (Fig. 1) than previously considered. Measurement of individual precursors alone to
interpret synthetic rate may be potentially confounding. The cellular regulation of cholesterol
synthesis occurring downstream of squalene has been investigated recently and identified the
two terminal enzymes in the pathway interact functionally, DHCR24 regulating the activity
of 7-dehydrocholesterol reductase (DHCR7) [16]. DHCR24 is also believed to have further
regulatory roles upstream in the pathway [16], however these roles have not been fully
15
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established and cholesterol synthetic regulation in the brain is still to be completely
understood.
Consistent with previous studies in the striatum of R6/1 [4] and R6/2 mice [7], our study did
not detect any significant alteration to the level of cholesterol in striatum and cortex of R6/1
mice compared to WT at any time-point. Previous studies also report conflicting results; a
small but significant decrease in cholesterol levels was detected in whole brain of the YAC
128 mouse model [17], and a significant increase of total striatal cholesterol was detected in a
knock-in mouse model [4]. These contradictions are probably due to differences in
cholesterol quantification methodologies used, that have been shown to significantly affect
the result obtained [48]. Analysis of different brain regions (striatum or whole brain
homogenates) are also likely to produce different results as there can be up to a 3-fold
difference in cholesterol levels between brain regions [7,44].
As WT and R6/1 mice aged, cholesterol synthetic precursor levels (lathosterol, lanosterol,
zymosterol and 24,25 dihydro lanosterol) decreased in the striatum, and to a lesser extent the
cortex. A similar reduction with age has been observed in human brain tissue [47]. An
increase in cholesterol levels during aging suggests that metabolic pathways may also have a
significant involvement in maintaining brain cholesterol levels, which has major implications
for brain ageing, an overarching risk factor across all neurodegenerative brain diseases.
At 28 weeks of age a significant (25%) reduction of 24-OHC levels in the R6/1 striatum
indicated that the relative decline of 24-OHC in R6/1 mice compared to WT is progressive
over the course of the disease, becoming more pronounced at later stages. Previous studies
have also identified a reduction of this metabolite in the brain and plasma of several other HD
mouse models [7,8]. Here we have also identified that 24-OHC levels increase in cortex and
striatum of R6/1 and WT during ageing, consistent with CYP46A1 enzyme levels increasing
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with age in the mouse brain [20]. The importance of increased cholesterol metabolism in the
ageing brain, and the potential effects of metabolic dysfunction in this HD model requires
further investigation.
A predominantly peripheral metabolite of cholesterol, 27-OHC was also significantly reduced
in R6/1 striatum by the age of 12 weeks, while cortex tissue had no significant alterations. 27OHC has a net movement from circulation into the brain [29] and reduced levels seen in R6/1
mice might be explained by a whole body metabolic dysfunction that is known to occur in
HD [49,50]. However, cortex tissue did not exhibit the same reduction of 27-OHC levels
observed in striatum, and therefore it is possible that enzymes that further metabolise 27OHC are upregulated, or enzymes capable of forming 27-OHC in brain are downregulated in
striatum.
Oxidation of cholesterol in the 5,6 position generates 7β-OHC and 7-KC that have been
demonstrated to be stable and reliable markers of oxidative stress, previously used in plasma
[36]. In contrast to our results that showed no change in COPs, a study in the striatum of R6/1
mice did observe a time-dependant increase of lipid peroxidation using a less sensitive and
specific lipid fluorescence based assay [51]. Since cholesterol is highly abundant in the brain,
the presence of oxidative stress would be expected to increase the formation of COPs in the
R6/1 mouse brain. Further research using oxidative damage biomarkers of multiple
biomolecules in a variety of brain regions is required to understand the exact role that
oxidative stress plays in the progression of HD pathophysiology.
Previous literature has typically studied either male or female R6/1 mice, in separate studies.
Here we have examined both sexes in parallel between 6 and 28 weeks of age to more
directly assess gender differences in the HD phenotype that have been previously reported.
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Despite differences in human and mouse metabolism the CAG expansion in transgenic R6/1
mice causes weight loss in line with that observed in human HD patients [52,53]. Consistent
with previous reports we observed a milder weight loss phenotype in females compared to
male R6/1 mice [54,55]. Female R6/1 weight gain was significantly slower than WT mice
prior to significant weight loss from 19 week of age, suggesting a metabolic abnormality
from early life. Body weight of male R6/1 mice was variable and a significant difference in
weight gain prior to weight loss was not detected. The primary cause of weight loss is
unlikely due to lack of feeding since it has been reported that R6/1 mice have a similar food
intake to WT mice whilst still exhibiting a distinct weight loss profile [39]. Food intake of
R6/1 mice was not measured in this study to reduce stress on animals being isolated and
reunited. During the progression of disease in R6/1 mice, both male and female mice showed
a progressive loss of motor skills that were quantified by Rotarod. Despite the same
environmental and handling conditions, high variation between mice reduced the statistical
power and gender differences in the progression of the motor deficit could not be
conclusively demonstrated. Impaired motor performance at the end time-point was
comparable between male and female R6/1 mice.
In this study we have comprehensively profiled cholesterol synthetic and metabolic changes
in R6/1 mice using GC-MS/MS and found similar reductions in the cholesterol synthetic
precursors previously reported in the R6/2 model. The novel measurement of desmosterol
and 7-dehydrocholesterol in R6/1 mice in this study has revealed potentially more complex
dysregulation of the cholesterol synthetic pathway in HD. It has highlighted the specific
accumulation of desmosterol in R6/1 brain tissue that is potentially due to reduced activity of
DHCR24. Reduction of 24-OHC and 27-OHC in the striatum of R6/1 mice compared to WT
littermates suggests that multiple pathways of cholesterol metabolism are perturbed in the
R6/1 brain. Comprehensive and sensitive analysis of sterol compounds in the brain of R6/1
18
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mice during progression of HD provides a new insight into synthetic and metabolic changes
occurring in this model of HD. Novel data on age-related changes occurring in the brain also
offers further information on sterol-related mechanisms that may influence other
neurodegenerative processes that typically manifest in the aged brain.
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Figure legends

Fig. 1 Simplified pathway showing cholesterol synthesis, metabolism and free radical
oxidation relevant to this study. The lower cholesterol synthetic (downstream of squalene)
pathway is branched into the Kandutsch-Russell pathway (via lathosterol) and Bloch pathway
(via desmosterol). Major metabolic pathways of cholesterol involve the enzymatic
hydroxylation of cholesterol by; cholesterol 24-hydroxylase (CYP46A1) to form 24hydroxycholesterol (24-OHC), and cholesterol 27-hydroxylase (CYP27A1) to form 27hydroxycholesterol (27-OHC). Free radical mediated oxidation of cholesterol can also occur.
Reactive oxygen species (ROS) form 7-Ketocholesterol and 7β-hydroxycholesterol. The
position of delta(24)-sterol reductase (DHCR24), a cholesterol synthetic enzyme is also
shown. Broken lines indicate intermediates that have not been shown in this simplified
scheme
Fig. 2 Progression of the physical phenotype in male and female R6/1 mice. (A) R6/1 mice
had significantly reduced body weight compared to WT over the course of the study (p <
0.0001). The R6/1 weight loss phenotype is more severe in male mice compared to females.
Male R6/1 mice begin to lose weight after 16 weeks compared to 19 weeks in females. The
rate of weight gain prior to weight loss was significantly slower in R6/1 females compared to
WT (p = 0.00012) while no difference was observed in male mice. (B) R6/1 mice develop a
phenotype where the hind paws are clasped to the body when suspended by the tail. Male
R6/1 mice exhibited the phenotype prior to females; the occurrence of the phenotype
increased in the population during ageing with 60% of the R6/1 mice showing a positive
clasping phenotype by 28 weeks. A small proportion of WT mice appeared to exhibit a half
clasp phenotype during the course of the study. (C) The motor performance of mice was
tested throughout the study and a progressive decline was found in the ability of R6/1 male
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and female mice to run on an accelerating rod when compared to WT (p = 0.0016 and 0.0004
respectively). No difference between male and female mice with the same genotype was
detected. Closed circles represent R6/1, open circles represent WT. n = 5 per group. Error
bars represent ± SEM
Fig. 3 Brain mass of R6/1 mice during disease progression. Brain mass was significantly
reduced in both R6/1 male and female mice compared to WT at later stages. The difference
between WT and R6/1 male mice was highly significant at 20, 24 and 28 weeks. A significant
difference between R6/1 and WT female mice was detected at 12 and 20 weeks, becoming
highly significant at 24 and 28 weeks. The brain mass was measured from mice sacrificed at
lipid analysis time points; each point represents 5-7 mice. Closed circles represent R6/1, open
circles represent WT. Error bars represent ± SEM. 2-way ANOVA Bonferroni post-test *p <
0.05 ***p < 0.0001
Fig. 4 Cholesterol synthetic precursor levels in striatum tissue of R6/1 and WT littermates.
Extracted sterols were quantified using heavy isotope mass dilution GC-MS/MS. (A)
Lathosterol, (B) lanosterol and (C) zymosterol levels were significantly reduced early in the
R6/1 mice compared to WT. (D) 24,25 dihydro lanosterol showed a trend to be decreased in
R6/1 mice however there was no significant difference between WT and R6/1 at any timepoint. Lanosterol, lathosterol, zymosterol and 24,25 dihydro lanosterol decreased over time in
both R6/1 and WT mice (p < 0.01). (E) Desmosterol did not significantly decline in R6/1
mice, and was significantly elevated at 20 and 28 weeks compared to control. (F) 7Dehydrocholesterol did not significantly decline in R6/1 mice and no significant differences
were detected between R6/1 and WT at any time point. Each data point represents combined
results from male and female mice, n = 10-13 per group. Closed circles represent R6/1, open
circles represent WT. Error bars represent ± SEM. 2-way ANOVA Bonferroni post-test *p <
0.05 **p < 0.01 ***p < 0.0001. t-test Ψp < 0.05
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Fig. 5 Cholesterol synthetic precursor levels in cortex tissue of R6/1 and WT littermates.
Extracted sterols were quantified using heavy isotope mass dilution GC-MS/MS. (A)
Lathosterol and (B) lanosterol levels were significantly reduced early in R6/1 mice compared
to WT. (C) Zymosterol was significantly reduced in R6/1 at the end time point. (D) 24,25
dihydro lanosterol had a trend to be reduced however there was no significant difference
between WT and R6/1 at any time-point. Zymosterol, lanosterol and 24,25 dihydro lanosterol
decreased in R6/1 over time while WT levels remained unchanged (p < 0.01). Lathosterol
levels decreased both in R6/1 and WT at a similar rate. (E) Desmosterol levels did not change
over time in R6/1 or WT mice, however desmosterol was elevated in R6/1 mice at 28 weeks.
(F) 7-Dehydrocholesterol did not significantly decline in R6/1 mice and no significant
differences were detected between R6/1 and WT at any time point.

Each data point

represents combined results from male and female mice, n = 10-13 per group. Closed circles
represent R6/1, open circles represent WT. Error bars represent ± SEM. 2-way ANOVA
Bonferroni post-test *p < 0.05 **p < 0.01 ***p < 0.0001. t-test Ψp < 0.05
Fig. 6 The level of cholesterol and cholesterol metabolites in striatum and cortex tissue of
R6/1 and WT littermates. Extracted sterols were quantified using heavy isotope mass dilution
GC-MS/MS. 24(S)-Hydroxycholesterol was significantly reduced in striatum of R6/1 mice
compared to WT at the end stage of the study. A significant reduction in 27hydroxycholesterol levels was detected at 12, 20, 24 and 28 weeks in the R6/1 striatum. An
effect of genotype on cortical levels of 24-hydroxycholesterol and 27-hydroxycholesterol was
not detected at any time point. Cholesterol levels were unaltered between R6/1 and WT mice
in both striatum and cortex at all time-points examined. A significant increase in 24hydroxycholesterol and cholesterol levels over time was detected in both regions (p < 0.01
and p < 0.05 respectively). Each data point represents combined results from male and female
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mice, n = 10-13 per group. Closed circles represent R6/1, open circles represent WT. Error
bars represent ± SEM. Bonferroni post-test *p < 0.05 **p < 0.01
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Supplemental Table 1 Absolute values of sterols in male R6/1 and WT cortex and striatum. GC‐MS/MS was used to analyse lipids extracted from mouse brain tissue at
various stages of the disease. Values represent ng/mg tissue ± SD.

Cortex

Striatum

6 week
Lathosterol
Lanosterol
Zymosterol
24,25 diH lan.
Desmosterol
7‐DHC
24‐OHC
27‐OHC
7‐KC
7β‐OHC
Cholesterola
Lathosterol
Lanosterol
Zymosterol
24,25 diH lan.
Desmosterol
7‐DHC
24‐OHC
27‐OHC
7‐KC
7β‐OHC
Cholesterola

WT
54.8 ± 5.6
13.6 ± 3.8
5.0 ± 1.3
0.34 ± 0.22
57.0 ± 9.1
63.0 ± 15.9
48.5 ± 8.7*
0.039 ± 0.02
0.67 ± 0.26
0.36 ± 0.12
15.1 ± 1.1
33.5 ± 8.7
7.9 ± 1.4
2.4 ± 0.66
0.33 ± 0.06
32.8 ± 14.9
39.5 ± 17.2
28.4 ± 9.5
0.038 ± 0.02
0.27 ± 0.12*
0.14 ± 0.07
9.5 ± 2.6

HD
41.7 ± 6.7
13.1 ± 3.6
4.0 ± 0.9
0.39 ± 0.19
57.7 ± 3.8*
59.0 ± 4.9*
42.3 ± 4.8*
0.034 ± 0.01
0.66 ± 0.29*
0.36 ± 0.17
13.6 ± 4.3
27.7 ± 11.2
8.3 ± 2.9
2.9 ± 1.1
0.40 ± 0.17
36.8 ± 9.2
41.2 ± 9.9
27.3 ± 7.5
0.030 ± 0.008
0.32 ± 0.13
0.18 ± 0.10
9.2 ± 2.8

Male
20 week

12 week
WT
43.2 ± 6.2
10.8 ± 1.7
3.2 ± 0.4
0.33 ± 0.09
31.1 ± 9.6*
43.5 ± 22.4
46.8 ± 4.1
0.078 ± 0.02
0.65 ± 0.18
0.45 ± 0.19
17.8 ± 3.1
34.7 ± 14.8
7.9 ± 2.7
2.9 ± 0.6
0.32 ± 0.11
34.6 ± 16.3
39.9 ± 6.0
29.7 ± 7.8
0.037 ± 0.01
0.51 ± 0.04
0.40 ± 0.11
13.8 ± 1.8

HD
20.0 ± 4.8
8.3 ± 2.5
2.2 ± 0.4
0.24 ± 0.18
39.7 ± 17.2
48.4 ± 21.8
39.7 ± 4.1
0.051 ± 0.01
0.65 ± 0.15
0.54 ± 0.27
19.9 ± 1.4
14.8 ± 4.1
5.7 ± 1.4
2.5 ± 0.6
0.22 ± 0.07
42.4 ± 16.4
40.5 ± 12.0
33.5 ± 7.5
0.038 ± 0.01
0.50 ± 0.09
0.35 ± 0.14
14.6 ± 2.0

WT
41.6 ± 5.7
13.6 ± 2.7
2.9 ± 0.63
0.26 ± 0.05
35.8 ± 5.1
54.3 ± 16.8
57.6 ± 11.2
0.083 ± 0.03
0.30 ± 0.003
0.26 ± 0.005
21.5 ± 2.6
34.5 ± 10.8
12.3 ± 4.7
2.7 ± 0.6
0.37 ± 0.18
41.9 ± 12.9*
44.1 ± 6.4
40.3 ± 7.7
0.099 ± 0.06*
0.37 ± 0.11
0.12 ± 0.03
10.5 ± 2.0

HD
17.8 ± 6.1
8.7 ± 3.4
2.2 ± 0.83
0.19 ± 0.06
41.7 ± 12.6
46.7 ± 14.6
48.6 ± 15.1
0.052 ± 0.02
0.28 ± 0.009
0.26 ± 0.010
21.7 ± 6.0
19.5 ± 3.1
7.4 ± 1.7
2.0 ± 0.3
0.32 ± 0.17
47.3 ± 7.3
44.5 ± 13.2
37.4 ± 9.0
0.071 ± 0.03*
0.58 ± 0.16
0.16 ± 0.12
12.8 ± 1.4

24 week
WT
HD
43.8 ± 10.7
12.6 ± 3.5
12.2 ± 4.0
4.5 ± 1.3
3.5 ± 0.88
1.8 ± 0.36
0.31 ± 0.07
0.20 ± 0.07
39.8 ± 8.1
42.0 ± 4.6
37.9 ± 7.0
42.5 ± 12.6
53.3 ± 8.5
45.5 ± 5.2
0.075 ± 0.012
0.051 ± 0.014
0.58 ± 0.19
0.52 ± 0.11
0.21 ± 0.06
0.22 ± 0.06
19.1 ± 1.8*
18.9 ± 1.9
32.1 ± 11.9
14.8 ± 3.3
6.7 ± 2.3
4.2 ± 1.2
3.0 ± 1.2
2.7 ± 0.85
0.22 ± 0.07
0.14 ± 0.04
27.0 ± 9.5
33.1 ± 9.4
31.0 ± 7.0
30.6 ± 9.9
23.6 ± 5.7*
26.2 ± 6.7
0.034 ± 0.007
0.032 ± 0.011
0.31 ± 0.08
0.22 ± 0.04*
0.12 ± 0.02
0.15 ± 0.07
11.0 ± 2.1
10.4 ± 1.9

28 week
WT
HD
31.4 ± 6.0
8.7 ± 2.7
8.9 ± 2.5*
4.7 ± 1.7
2.7 ± 0.4
1.5 ± 0.6
0.19 ± 0.09
0.13 ± 0.08
33.0 ± 5.9
40.1 ± 7.3
57.3 ± 15.3
68.7 ± 15.3
53.7 ± 3.4*
40.5 ± 8.3
0.043 ± 0.02
0.024 ± 0.01
0.65 ± 0.29
0.41 ± 0.17
0.28 ± 0.13
0.23 ± 0.11
19.2 ± 3.0
19.8 ± 3.2
28.8 ± 5.5
14.6 ± 3.1
8.4 ± 1.3
4.6 ± 1.2
2.9 ± 0.30
2.0 ± 0.42
0.32 ± 0.03
0.25 ± 0.09
32.0 ± 8.1
38.0 ± 2.1
45.6 ± 7.4
49.7 ± 6.2
46.3 ± 6.7
42.4 ± 6.7
0.051 ± 0.008 0.044 ± 0.01
0.86 ± 0.50
1.0 ± 1.05
0.43 ± 0.30
0.20 ± 0.09
15.4 ± 1.9
17.6 ± 2.9

24, 25 diH lan. = 24, 25 dihydro lanosterol; 7‐DHC = 7‐dehydrocholesterol; 24‐OHC = 24(S)‐hydroxycholesterol; 27‐OHC = 27‐hydroxycholesterol; 7‐KC = 7‐ketocholesterol;
7β‐OHC = 7β‐hydroxycholesterol. aValues expressed as µg/mg tissue. *Values identified to be significantly different between male and female of the same genotype, t‐test
p < 0.05.

33

34

Supplemental Table 2 Absolute values of sterols in female R6/1 and WT cortex and striatum. GC‐MS/MS was used to analyse lipids extracted from mouse brain tissue at
various stages of the disease. Values represent ng/mg tissue ± SD.

Cortex

Striatum

6 week
Lathosterol
Lanosterol
Zymosterol
24,25 diH lan.
Desmosterol
7‐DHC
24‐OHC
27‐OHC
7‐KC
7β‐OHC
Cholesterola
Lathosterol
Lanosterol
Zymosterol
24,25 diH lan.
Desmosterol
7‐DHC
24‐OHC
27‐OHC
7‐KC
7β‐OHC
Cholesterola

WT
58.5 ± 13.7
17.1 ± 6.7
5.1 ± 1.2
0.44 ± 0.22
53.7 ± 9.1
70.9 ± 13.2
38.1 ± 7.5*
0.034 ± 0.02
0.84 ± 0.57
0.35 ± 0.28
14.5 ± 1.5
40.2 ± 10.3
9.4 ± 3.5
2.6 ± 0.44
0.45 ± 0.16
29.6 ± 5.1
40.6 ± 4.9
26.6 ± 4.8
0.034 ± 0.008
0.49 ± 0.18*
0.24 ± 0.12
10.9 ± 2.1

HD
36.4 ± 8.3
10.2 ± 3.3
3.6 ± 0.93
0.20 ± 0.14
42.9 ± 8.2*
46.9 ± 5.3*
34.8 ± 3.6*
0.030 ± 0.01
0.33 ± 0.06*
0.20 ± 0.05
13.1 ± 1.4
26.3 ± 10.4
7.4 ± 1.1
2.7 ± 0.69
0.35 ± 0.08
36.8 ± 10.0
39.1 ± 9.4
30.9 ± 7.6
0.033 ± 0.008
0.33 ± 0.11
0.22 ± 0.14
9.1 ± 2.4

Female
20 week

12 week
WT
46.6 ± 14.8
14.8 ± 5.9
3.6 ± 1.3
0.51 ± 0.26
47.8 ± 9.1*
56.8 ± 21.0
45.1 ± 4.2
0.067 ± 0.01
0.60 ± 0.21
0.44 ± 0.12
19.5 ± 3.5
43.9 ± 9.9
10.4 ± 3.3
3.2 ± 0.6
0.35 ± 0.15
33.6 ± 16.7
38.1 ± 6.1
30.4 ± 4.8
0.044 ± 0.02
0.49 ± 0.17
0.37 ± 0.17
16.6 ± 2.7

HD
19.7 ± 6.6
7.9 ± 2.8
2.1 ± 0.8
0.33 ± 0.20
40.4 ± 6.8
52.3 ± 10.6
43.1 ± 3.1
0.046 ± 0.02
0.70 ± 0.16
0.57 ± 0.18
20.3 ± 1.5
21.2 ± 6.1
7.0 ± 1.5
2.8 ± 0.4
0.24 ± 0.11
47.6 ± 18.6
41.8 ± 15.1
32.6 ± 2.5
0.047 ± 0.01
0.46 ± 0.18
0.37 ± 0.12
15.3 ± 2.3

WT
48.3 ± 4.1
15.2 ± 4.3
3.1 ± 0.74
0.30 ± 0.03
33.0 ± 5.0
45.3 ± 16.8
56.5 ± 4.7
0.071 ±
0.33 ± 0.008
0.23 ± 0.004
23.3 ± 4.4
41.6 ± 8.8
10.9 ± 2.6
2.4 ± 0.5
0.32 ± 0.08
26.1 ± 7.3*
42.5 ± 7.3
38.7 ± 17.4

HD
18.7 ± 6.4
8.3 ± 3.4
1.9 ± 0.43
0.21 ± 0.05
41.3 ± 6.5
44.0 ± 13.2
49.5 ± 7.9
0.049 ± 0.12
0.32 ± 0.008
0.23 ± 0.005
24.8 ± 4.1
15.5 ± 6.3
5.5 ± 1.6
1.9 ± 0.6
0.17 ± 0.11
44.0 ± 2.9
46.0 ± 16.6
37.2 ± 3.6

0.021 ± 0.006*

0.017 ± 0.005*

0.46 ± 0.22
0.15 ± 0.06
12.2 ± 2.9

0.51 ± 0.25
0.16 ± 0.04
10.9 ± 1.9

24 week
WT
HD
33.5 ± 8.9
17.7 ± 6.8
9.8 ± 4.3
6.4 ± 1.9
3.0 ± 1.2
2.3 ± 0.98
0.33 ± 0.012
0.23 ± 0.05
37.0 ± 6.7
45.1 ± 5.4
42.9 ± 14.0
47.7 ± 16.6
46.5 ± 5.6
43.6 ± 7.4
0.078 ± 0.02
0.056 ± 0.008
0.49 ± 0.18
0.57 ± 0.19
0.20 ± 0.07
0.24 ± 0.06
16.4 ± 1.5*
18.0 ± 2.8
31.8 ± 7.9
15.6 ± 1.7
9.5 ± 2.2
4.6 ± 0.99
3.8 ± 0.94
2.7 ± 0.65
0.27 ± 0.07
0.14 ± 0.05
34.8 ± 12.5
39.5 ± 12.2
24.1 ± 7.5
31.3 ± 11.3
38.5 ± 9.5*
32.9 ± 5.8
0.060 ± 0.03
0.039 ± 0.01
0.33 ± 0.10
0.35 ± 0.11*
0.11 ± 0.02
0.18 ± 0.06
11.8 ± 3.04
10.9 ± 1.7

28 week
WT
HD
36.4 ± 7.8
5.7 ± 1.9
13.3 ± 3.0*
2.7 ± 1.4
2.7 ± 0.3
1.1 ± 0.8
0.21 ± 0.12
0.04 ± 0.03
33.4 ± 5.1
39.4 ± 4.0
56.5 ± 10.8
55.4 ± 16.1
61.9 ± 6.8*
49.3 ± 4.6
0.058 ± 0.02 0.028 ± 0.009
0.38 ± 0.05
0.57 ± 0.19
0.20 ± 0.07
0.25 ± 0.13
20.67 ± 1.7
20.4 ± 1.6
30.6 ± 6.1
15.3 ± 4.0
9.6 ± 0.94
5.3 ± 1.7
2.8 ± 0.50
2.0 ± 0.48
0.32 ± 0.05
0.23 ± 0.04
32.8 ± 7.9
38.5 ± 4.3
49.2 ± 5.5
50.4 ± 9.6
45.8 ± 10.9
37.8 ± 3.7
0.055 ± 0.007 0.033 ± 0.007
0.91 ± 0.62
0.78 ± 0.68
0.35 ± 0.35
0.23 ± 0.11
15.5 ± 1.8
15.2 ± 3.1

24, 25 diH lan. = 24, 25 dihydro lanosterol; 7‐DHC = 7‐dehydrocholesterol; 24‐OHC = 24(S)‐hydroxycholesterol; 27‐OHC = 27‐hydroxycholesterol; 7‐KC = 7‐ketocholesterol;
7β‐OHC = 7β‐hydroxycholesterol. aValues expressed as µg/mg tissue. *Values identified to be significantly different between male and female of the same genotype, t‐test
p < 0.05.
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Supplemental Table 3 Absolute values of sterols in combined sexes R6/1 and WT cortex and striatum. GC‐MS/MS was used to analyse lipids extracted from mouse brain
tissue at various stages of the disease. Values represent ng/mg tissue ± SD.

Cortex

Striatum

6 week
Lathosterol
Lanosterol
Zymosterol
24,25 diH lan.
Desmosterol
7‐DHC
24‐OHC
27‐OHC
7‐KC
7β‐OHC
Cholesterola
Lathosterol
Lanosterol
Zymosterol
24,25 diH lan.
Desmosterol
7‐DHC
24‐OHC
27‐OHC
7‐KC
7β‐OHC
Cholesterola

Combined
20 week

12 week

24 week

28 week

WT

HD

WT

HD

WT

HD

WT

HD

WT

HD

56.5 ± 9.6
15.2 ± 5.4
5.0 ± 1.2
0.38 ± 0.21
55.5 ± 8.9
66.6 ± 14.7
43.7 ± 9.5
0.037 ±
0.74 ± 0.40
0.36 ± 0.19
14.8 ± 1.3
36.6 ± 9.7
8.6 ± 2.6
2.5 ± 0.55
0.39 ± 0.12
31.3 ± 11.2
40.0 ± 12.6
27.5 ± 7.5
0.036 ±
0.37 ± 0.18
0.19 ± 0.11
10.1 ± 2.4

38.8 ± 7.8
11.5 ± 3.6
3.8 ± 0.88
0.29 ± 0.19
49.6 ± 9.9
52.2 ± 7.8
38.2 ± 5.6
0.033 ±
0.48 ± 0.26
0.27 ± 0.14
13.3 ± 2.9
27.0 ± 10.2
7.8 ± 2.0
2.8 ± 0.84
0.37 ± 0.12
36.6 ± 9.2
40.1 ± 9.2
29.3 ± 7.5

45.0 ± 11.3
12.9 ± 4.8
3.5 ± 0.9
0.44 ± 0.22
40.2 ± 12.4
50.8 ± 21.6
45.5 ± 4.1
0.071 ±
0.59 ± 0.17
0.42 ± 0.15
18.5 ± 3.4
39.7 ± 9.3
9.2 ± 3.2
3.0 ± 0.6
0.34 ± 0.13
34.1 ± 15.7
42.8 ± 6.4
30.1 ± 6.0
0.041 ±
0.50 ± 0.12
0.38 ± 0.14
15.4 ± 2.7

19.8 ± 5.6
8.1 ± 2.5
2.2 ± 0.6
0.29 ± 0.19
40.1 ± 11.9
50.5 ± 15.8
41.0 ± 3.6
0.047 ±
0.67 ± 0.15
0.54 ± 0.22
19.9 ± 1.3
18.3 ± 6.1
6.4 ± 1.5
2.7 ± 0.5
0.23 ± 0.09
45.3 ± 17.0
45.3 ± 14.4
33.0 ± 5.1
0.043 ±
0.48 ± 0.14
0.36 ± 0.13
15.0 ± 2.1

44.6 ± 6.0
14.3 ± 3.4
3.0 ± 0.65
0.28 ± 0.05
34.5 ± 5.0
50.2 ± 16.6
57.1 ± 8.5
0.77 ± 0.02

18.3 ± 5.9
8.5 ± 3.2
2.0 ± 0.65
0.20 ± 0.05
41.5 ± 9.5
45.2 ± 13.2
49.1 ± 11.4
0.51 ± 0.15

0.032 ± 0.006

0.030 ± 0.008
0.025 ± 0.007

38.6 ± 10.7
11.0 ± 4.1
3.7 ± 1.0
0.32 ± 0.09
38.4 ± 7.2
40.4 ± 10.8
49.9 ± 7.7
0.076 ± 0.02
0.53 ± 0.18
0.21 ± 0.06
17.8 ± 2.1
31.9 ± 9.5
8.1 ± 2.6
3.4 ± 1.1
0.24 ± 0.06
30.9 ± 11.2
27.6 ± 7.7
31.0 ± 10.8
0.047 ± 0.02
0.32 ± 0.08
0.11 ± 0.02
11.4 ± 2.5

14.9 ± 5.6
5.4 ± 1.9
2.0 ± 0.71
0.21 ± 0.06
43.4 ± 5.0
44.9 ± 14.0
44.6 ± 6.0
0.053 ± 0.01
0.54 ± 0.15
0.23 ± 0.06
18.5 ± 2.3
15.2 ± 2.6
4.4 ± 1.1
2.7 ± 0.73
0.14 ± 0.04
36.0 ± 10.7
30.9 ± 10.0
29.2 ± 6.9
0.035 ± 0.01
0.29 ± 0.11
0.16 ± 0.07
10.7 ± 1.7

33.9 ± 7.0
11.1 ± 3.5
2.7 ± 0.33
0.20 ± 0.10
33.2 ± 5.2
56.9 ± 12.8
57.8 ± 6.7
0.051 ±
0.52 ± 0.24
0.24 ± 0.11
20.0 ± 2.4
29.7 ± 5.6
9.0 ± 1.2
2.9 ± 0.39
0.32 ± 0.04
32.4 ± 7.5
47.4 ± 6.4
46.1 ± 8.5

7.2 ± 2.7
3.7 ± 1.8
1.3 ± 0.72
0.090 ±
39.8 ± 5.6
62.2 ± 16.4
44.9 ± 7.8
0.026 ±
0.49 ± 0.19
0.24 ± 0.11
20.1 ± 2.4
15.0 ± 3.5
5.0 ± 1.4
2.0 ± 0.42
0.24 ± 0.07
38.3 ± 3.2
50.0 ± 7.6
40.1 ± 5.6
0.039 ±
0.90 ± 84
0.22 ± 0.09
16.4 ± 3.1

0.032 ± 0.007

0.33 ± 0.11
0.20 ± 0.12
9.2 ± 2.5

0.24 ±
22.3 ± 3.5
35.8 ± 9.5
7.7 ± 2.4
2.5 ± 0.4
0.32 ± 0.12
35.3 ± 14.0
43.3 ± 6.5
39.6 ± 13.0
0.047 ±
0.41 ± 0.17
0.13 ±
11.0 ± 2.5

23.3 ± 5.2
17.5 ± 5.1
4.5 ± 1.3
1.9 ± 0.4
0.25 ± 0.15
45.7 ± 5.5
45.3 ± 14.4
37.3 ± 6.5
0.044 ±
0.54 ± 0.20
0.16 ±
11.9 ± 1.7

0.053 ± 0.007

0.88 ± 0.53
0.40 ± 0.30
15.5 ± 1.7

24, 25 diH lan. = 24, 25 dihydro lanosterol; 7‐DHC = 7‐dehydrocholesterol; 24‐OHC = 24(S)‐hydroxycholesterol; 27‐OHC = 27‐hydroxycholesterol; 7‐KC = 7‐ketocholesterol;
7β‐OHC = 7β‐hydroxycholesterol. aValues expressed as µg/mg tissue.
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